ICIs enhances the anti-tumor activity of the immune system by inhibiting immune downregulating factors such as programmed cell death receptor 1 (PD-1), programmed cell death ligand 1 (PD-L1), and cytotoxic T lymphocyte antigen 4 (CTLA-4) (74). This evidence concerns the gene CTLA4 and neoplasm.